Topical sirolimus in dermatology: a systematic review

西罗莫司 皮肤病科 医学 不利影响 药理学 外科
作者
Usamah M Afzal,Mohammad Alazemi,Omar M. E. Ali,Faisal R. Ali,John T. Lear
出处
期刊:Clinical and Experimental Dermatology [Oxford University Press]
被引量:1
标识
DOI:10.1093/ced/llae275
摘要

Abstract Topical sirolimus is increasingly utilized off-licence to manage various dermatological conditions while avoiding typical adverse effects associated with systemic sirolimus. However, widespread use is limited by a highly heterogeneous evidence base of mixed quality. Our aim was to evaluate the current evidence base for the indications, efficacy and safety profile of topical sirolimus in dermatology. A literature search was conducted from 2005 to 4 July 2023, of English-language studies, with the following databases consulted: MEDLINE, PubMed, Embase, CENTRAL and EBSCO. Key words included ‘topical’, ‘rapamycin’, ‘sirolimus’ and ‘dermatology’. Data on drug efficacy, concentration, side-effects, cointerventions and follow-up were extracted. The search identified 202 studies, 71 of which met the inclusion criteria. Efficacy of topical sirolimus was demonstrated in facial angiofibromas (799 patients) compared with placebo across multiple randomized controlled trials, with a predominant concentration of 0.1%. Evidence was mixed for use of sirolimus in port-wine stains (61 patients), with evidence of effectiveness for combined sirolimus and pulsed-dye laser. Multiple case reports demonstrated clinical improvement with topical sirolimus in cutaneous vascular abnormalities (33 patients) at a higher concentration of 1%. Other applications of topical sirolimus were predominantly case reports, demonstrating generally favourable outcomes. Topical sirolimus was generally well tolerated; most reported adverse effects were localized irritation and pruritus. Ointment-based preparations and once-daily dosing appeared to confer a better side-effect profile. Most high-quality data pertain to the efficacy of topical sirolimus in treating facial angiofibromas in tuberous sclerosis. Outcomes are generally promising in other indications, with good tolerability, but data quality is mixed.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
爱吃大米发布了新的文献求助10
1秒前
laber应助满意小丸子采纳,获得30
1秒前
2秒前
郴欧尼发布了新的文献求助10
2秒前
含蓄洋葱发布了新的文献求助10
2秒前
温暖发布了新的文献求助30
2秒前
香蕉觅云应助阿九采纳,获得10
2秒前
asdfks发布了新的文献求助10
3秒前
3秒前
4秒前
丘比特应助有趣的灵魂采纳,获得10
4秒前
5秒前
ilawuyou完成签到,获得积分10
5秒前
坚强似狮发布了新的文献求助10
6秒前
酷波er应助XianyunWang采纳,获得10
6秒前
6秒前
丘比特应助zyx采纳,获得10
7秒前
8秒前
科研八戒发布了新的文献求助10
8秒前
9秒前
传奇3应助爱吃大米采纳,获得10
9秒前
含蓄洋葱完成签到,获得积分10
9秒前
10秒前
弋戈完成签到,获得积分10
10秒前
大模型应助chunyeliangchuan采纳,获得10
10秒前
CipherSage应助沉淀采纳,获得10
11秒前
原点完成签到,获得积分10
12秒前
不配.应助梵高采纳,获得20
13秒前
果汁鱼完成签到 ,获得积分10
13秒前
完美世界应助阔达的秀发采纳,获得10
14秒前
14秒前
Hello应助科研通管家采纳,获得10
14秒前
14秒前
CipherSage应助科研通管家采纳,获得10
14秒前
ilawuyou关注了科研通微信公众号
15秒前
今后应助科研通管家采纳,获得10
15秒前
丘比特应助科研通管家采纳,获得10
15秒前
我是老大应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
高分求助中
(禁止应助)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
Plutonium Handbook 4000
International Code of Nomenclature for algae, fungi, and plants (Madrid Code) (Regnum Vegetabile) 1500
Functional High Entropy Alloys and Compounds 1000
Building Quantum Computers 1000
Molecular Cloning: A Laboratory Manual (Fourth Edition) 500
Social Epistemology: The Niches for Knowledge and Ignorance 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4233611
求助须知:如何正确求助?哪些是违规求助? 3767165
关于积分的说明 11836017
捐赠科研通 3425357
什么是DOI,文献DOI怎么找? 1879871
邀请新用户注册赠送积分活动 932579
科研通“疑难数据库(出版商)”最低求助积分说明 839736